Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Hormonal Therapy for the Treatment of Primary HER2-Positive Breast Cancer: One More Step Toward Chemotherapy-Free Therapy

被引：18
作者：
Prat, Aleix [1 ]
Baselga, Jose [2 ]
机构：
[1] Vall dHebron Inst Oncol, Barcelona, Spain
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 14期
关键词：
PHASE-II; TRASTUZUMAB RESISTANCE; ADJUVANT CHEMOTHERAPY; PLUS TRASTUZUMAB; OPEN-LABEL; LAPATINIB; MULTICENTER; PERTUZUMAB; COMBINATION; DOCETAXEL;
D O I：
10.1200/JCO.2012.48.4998
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1703 / 1706
页数：4
相关论文
共 35 条
  • [1] [Anonymous], GUID IND PATH COMPL
  • [2] [Anonymous], 35 ANN SAN ANT BREAS
  • [3] Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
    Arpino, Grazia
    Gutierrez, Carolina
    Weiss, Heidi
    Rimawi, Mothaffar
    Massarweh, Suleiman
    Bharwani, Lavina
    De Placido, Sabino
    Osborne, C. Kent
    Schiff, Rachel
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (09): : 694 - 705
  • [4] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Baselga, Jose
    Bradbury, Ian
    Eidtmann, Holger
    Di Cosimo, Serena
    de Azambuja, Evandro
    Aura, Claudia
    Gomez, Henry
    Dinh, Phuong
    Fauria, Karine
    Van Dooren, Veerle
    Aktan, Gursel
    Goldhirsch, Aron
    Chang, Tsai-Wang
    Horvath, Zsolt
    Coccia-Portugal, Maria
    Domont, Julien
    Tseng, Ling-Min
    Kunz, Georg
    Sohn, Joo Hyuk
    Semiglazov, Vladimir
    Lerzo, Guillermo
    Palacova, Marketa
    Probachai, Volodymyr
    Pusztai, Lajos
    Untch, Michael
    Gelber, Richard D.
    Piccart-Gebhart, Martine
    [J]. LANCET, 2012, 379 (9816) : 633 - 640
  • [5] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
    Baselga, Jose
    Cortes, Javier
    Kim, Sung-Bae
    Im, Seock-Ah
    Hegg, Roberto
    Im, Young-Hyuck
    Roman, Laslo
    Pedrini, Jose Luiz
    Pienkowski, Tadeusz
    Knott, Adam
    Clark, Emma
    Benyunes, Mark C.
    Ross, Graham
    Swain, Sandra M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) : 109 - 119
  • [6] Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
    Blackwell, Kimberly L.
    Burstein, Harold J.
    Storniolo, Anna Maria
    Rugo, Hope S.
    Sledge, George
    Aktan, Gursel
    Ellis, Catherine
    Florance, Allison
    Vukelja, Svetislava
    Bischoff, Joachim
    Baselga, Jose
    O'Shaughnessy, Joyce
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2585 - 2592
  • [7] *CLINICALTRIALS, ALTTO ADJ LAP TRAST
  • [8] ClinicalTrials.gov, STUD PERT ADD CHEM H
  • [9] Cortazar P, 2012, 35 ANN SAN ANT BREAS
  • [10] Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Cortes, Javier
    Fumoleau, Pierre
    Bianchi, Giulia Valeria
    Petrella, Teresa M.
    Gelmon, Karen
    Pivot, Xavier
    Verma, Shailendra
    Albanell, Joan
    Conte, Pierfranco
    Lluch, Ana
    Salvagni, Stefania
    Servent, Veronique
    Gianni, Luca
    Scaltriti, Maurizio
    Ross, Graham A.
    Dixon, Joanna
    Szado, Tania
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1594 - 1600
1234